非霍奇金淋巴瘤外周血尿激酶型纤溶酶原激活物及其受体测定的临床意义

 目的 研究非霍奇金淋巴瘤（NHL）患者血中尿激酶型纤溶酶原激活物（uPA）、尿激酶型纤溶酶原激活物受体（uPAR）、纤溶酶原激活剂抑制物-1（PAI-1）水平与NHL发生、发展及预后的关系。方法 采用ELISA方法检测38例初治NHL患者血中uPA，uPAR 及PAI-1水平，分析与不同临床分期、治疗效果、乳酸脱氢酶（LDH）的相关性。结果 NHL患者血uPA，uPAR及PAI-1水平均高于正常对照组（P＜0.05）， NHL患者LDH值增高组与LDH正常组比较uPAR增高（P＜0.05），uPA，uPAR与LDH三者之间呈正相关（P＜0.01）。结论 uPA及可溶性uPA 受体（suPAR）在NHL的发生、发展中起作用，suPAR可以作为判断NHL肿瘤负荷和预后的指标。

The relationship between urokinase plasminogen activator system and non-Hodgkin lymphoma

Objection To investigate the relationship between urokinase plasminogen activator (uPA), urokinase-type plasminogen activators receptor (uPAR), plasminogen activator inhibitor type 1(PAI-1) in NHL patient's blood and NHL cell proliferation, invasion and prognosis. Methods The NHL patients plasma levels of uPA, uPAR and PAI-1 were measured by enzyme linked-immunoadsorbent assay （ELISA） in thirty-eight patients. We compared the NHL patients' uPA, uPAR and PAI-1 with healthy men as control group, parameters with different groups divided by clinical stage, the level of blood LDH with treatment affection. We also analyzed the correlationship between uPA, uPAR, PAI-1 and LDH in NHL patients. Results The levels of plasma uPA, uPAR and PAI-1 are remarkable higher in patients than the control group (P ＜ 0.05). The levels of plasma uPA and uPAR in the group of Ⅲ and Ⅳ clinical stage are higher than the group of Ⅰ and Ⅱ clinical stage, but have no significant difference(P > 0.05). The levels of plasma uPAR is higher in the group of high Lactate dehydrogenase（LDH） than in the group of normal LDH (P < 0.05). The levels of plasma uPA, uPAR and LDH are correlated significantly with each other(P < 0.01). Conclusion The change in uPA system play an important role in NHL cell proliferation, invasion and prognosis. The levels of soluble uPAR (suPAR) can be used as the NHL load index and prognosis index in NHL patients.